A Phase 1 Study of CMC-544 [inotuzumab ozogamicin] Administered as a Single Agent in Subjects With B-Cell Non-Hodgkin's Lymphoma.
Phase of Trial: Phase I
Latest Information Update: 08 Sep 2010
At a glance
- Drugs Inotuzumab ozogamicin (Primary)
- Indications B cell lymphoma
- Focus Adverse reactions
- Sponsors Wyeth
- 08 Sep 2010 Actual end date changed from Jan 2008 to Jul 2008 as reported by ClinicalTrials.gov.
- 21 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jun 2010 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.